Understanding hormonal and metabolic factors in pulmonary arterial hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the hormonal and metabolic pathways involved in pulmonary arterial hypertension (PAH), particularly focusing on gender differences in disease prevalence and progression. The research will investigate how estrogen and testosterone levels may influence the condition, with the goal of confirming earlier findings in a larger patient cohort. Additionally, the study will assess the metabolic syndrome's role in PAH and evaluate potential therapeutic approaches based on these insights. By understanding these interactions, the study seeks to pave the way for improved treatment strategies for PAH.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Project 1

Inclusion:

1. Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons
2. Age 0-90, age 12-90 for skin biopsy

Exclusion:

1. Other diagnosis
2. Age greater than 90, age less than 12 or greater than 90 for skin biopsy

Project 2

Inclusion:

1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
2. 0-90
3. Subjects with reasonably easy access to clinic for blood collection and other testing
4. Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing

Exclusion:

1. Other diagnosis
2. 0-90
3. Subjects with difficulty reaching clinic for blood collection and other testing
4. Subjects unable to tolerate fasting state

Project 3

Inclusion:

1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
2. 7-90

Exclusion:

1. Other diagnosis
2. Age less than 7 or greater than 90

   \-

   Exclusion Criteria:

   \-

Where it's running

• Vanderbilt University Medical Center
  Nashville, Tennessee, United States Recruiting

Study contacts

• Principal investigator: James E Loyd, MD — Vanderbilt University Medical Center
• Study coordinator: Kelly L Fox
• Email: Kelly.Burke@vumc.org
• Phone: 800-288-0378

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding risk and resilience in pulmonary arterial hypertension

  This study is trying to understand why some people with certain genetic changes get pulmonary arterial hypertension while others don’t, by looking at different markers in their bodies over time.

  Recruiting Vanderbilt University Medical Center · Nashville, Tennessee · NCT05584722

• Investigating Lipid Accumulation in the Right Ventricle of Patients with Pulmonary Arterial Hypertension

  This study is trying to see how fat buildup in the right side of the heart affects the health and exercise ability of people with pulmonary arterial hypertension.

  Recruiting Vanderbilt University Medical Center · Nashville, Tennessee · NCT05462574

• Using 129Xe MRI to Diagnose and Monitor Pulmonary Arterial Hypertension

  This study is testing if a special type of MRI can help doctors spot different types of Pulmonary Arterial Hypertension and track how the disease changes over time in people with this condition.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT06104228

• Understanding how low-load leg exercises affect muscle and blood flow in PAH patients

  This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07781709

• Sotatercept in Japanese children with pulmonary arterial hypertension

  This study tests whether sotatercept is safe and well tolerated in Japanese children with PAH when added to standard PAH treatment.

  Recruiting at 3 sites Phase 2 Merck Sharp & Dohme LLC · Izumi, Osaka and 2 other locations · NCT07646860

• DIAG723 in Adults With HHT

  A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.

  Recruiting at 3 sites Phase 1/2 Diagonal Therapeutics, Inc. · Camperdown, New South Wales and 10 other locations · NCT07623525

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.